Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics (Q31047131)

28 June 2017

1 reference

title

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics (English)

1 reference

28 June 2017

0 references

0 references

1

Colin L Masters

1 reference

28 June 2017

Roberto Cappai

2

1 reference

28 June 2017

Kevin J Barnham

series ordinal

3

1 reference

28 June 2017

Victor L Villemagne

series ordinal

4

1 reference

28 June 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Journal of Neurochemistry

28 June 2017

1 reference

28 June 2017

97

1 reference

28 June 2017

1700-1725

1 reference

28 June 2017

6

1 reference

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

28 June 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of beta-amyloid-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Oxidative stress and gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Neurodegenerative diseases and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The female sex hormone oestrogen as a neuroprotectant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Toxicity of enzymically-oxidized low-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Budesonide epimer R, LAU-8080 and phenyl butyl nitrone synergistically repress cyclooxygenase-2 induction in [IL-1beta+Abeta42]-stressed human neural cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Metal complexing agents as therapies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The metallobiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Does mitochondrial respiratory chain dysfunction have a role in common neurodegenerative disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

M1 receptors play a central role in modulating AD-like pathology in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Mitochondrial free radical generation, oxidative stress, and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Cholesterol oxides induce programmed cell death in microglial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The role of caspase cleavage of tau in Alzheimer disease neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Blockade of gamma-secretase activity within the hippocampus enhances long-term memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Oxidative damage to DNA in mammalian chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Untangling memory deficits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Prospects for pharmacological intervention in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Design of peptidyl compounds that affect beta-amyloid aggregation: importance of surface tension and context

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Estrogen therapy fails to alter amyloid deposition in the PDAPP model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Synthesis of 4,5-dianilinophthalimide and related analogues for potential treatment of Alzheimer's disease via palladium-catalyzed amination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Inhibition of platelet activation by the Alzheimer's disease amyloid precursor protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

19F and 1H MRI detection of amyloid beta plaques in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

X-ray crystal structure of the protease inhibitor domain of Alzheimer's amyloid beta-protein precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Clioquinol treatment in familiar early onset of Alzheimer's disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Fucoidan inhibits cellular and neurotoxic effects of beta-amyloid (A beta) in rat cholinergic basal forebrain neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The channel hypothesis of Alzheimer's disease: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Small vessel disease and Alzheimer's dementia: pathological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Mild cognitive impairment and Alzheimer disease: regional diffusivity of water

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Disruption of calcium homeostasis in the pathogenesis of Alzheimer's disease and other conformational diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Serotonin 1A receptors in the living brain of Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

MRI measures of entorhinal cortex vs hippocampus in preclinical AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

An inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: evidence for distinct molecular processes underlying tau abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Substituted thiazolamide coupled to a redox delivery system: a new gamma-secretase inhibitor with enhanced pharmacokinetic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Identification, design, synthesis, and pharmacological activity of (4-ethyl-piperazin-1-yl)-phenylmethanone derivatives with neuroprotective properties against beta-amyloid-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Hsp20, a novel alpha-crystallin, prevents Abeta fibril formation and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamate toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Design and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Abeta-42 deposition precedes other changes in PS-1 Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Nanoparticle and other metal chelation therapeutics in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Copper, iron and zinc in Alzheimer's disease senile plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Characterization of 8-epiprostaglandin F2alpha as a marker of amyloid beta-peptide-induced oxidative damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Neuronal and glial calcium signaling in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Activation of microglial cells by beta-amyloid protein and interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

A chemically modified preparation of alpha2-macroglobulin binds beta-amyloid peptide with increased affinity and inhibits Abeta cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

{beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Antioxidants as treatment for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Alzheimer's disease-do tauists and baptists finally shake hands?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Sites of tau important for aggregation populate {beta}-structure and bind to microtubules and polyanions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The amyloid precursor protein locus and very-late-onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Electron transport chain defects in Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Neuropathology of Alzheimer's disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

In vivo reduction of amyloid-beta by a mutant copper transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Biochemical and cell-based assays for characterization of BACE-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Alzheimer disease beta-amyloid activity mimics cholesterol oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Enhanced delivery of gamma-secretase inhibitor DAPT into the brain via an ascorbic acid mediated strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Trolox and 17beta-estradiol protect against amyloid beta-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Tau is essential to beta -amyloid-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

In vivo amyloid imaging in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Tau suppression in a neurodegenerative mouse model improves memory function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Blocking the cleavage at midportion between gamma- and epsilon-sites remarkably suppresses the generation of amyloid beta-protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Current progress in beta-amyloid immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Loss of apolipoprotein E receptor LR11 in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Increased lipoprotein oxidation in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Alzheimer's disease is a synaptic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Statins prevent beta-amyloid inhibition of sympathetic alpha7-nAChR-mediated nitrergic neurogenic dilation in porcine basilar arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia, and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Early AGEing and Alzheimer's.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Iron accumulation in Alzheimer disease is a source of redox-generated free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Variable phenotype of Alzheimer's disease with spastic paraparesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Regulation of NMDA receptor trafficking by amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Cybrids in Alzheimer's disease: a cellular model of the disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Alzheimer's disease: channeling APP to non-amyloidogenic processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Mapping hippocampal and ventricular change in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Therapeutic strategies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Effects of RNAi-mediated silencing of PEN-2, APH-1a, and nicastrin on wild-type vs FAD mutant forms of presenilin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Structures of eukaryotic ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Specific interaction of VEGF165 with beta-amyloid, and its protective effect on beta-amyloid-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Transgenic potato expressing Abeta reduce Abeta burden in Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.03989.X

10.1111/J.1471-4159.2006.03989.X

21 January 2018

Identifiers

DOI

1 reference

28 June 2017

1 reference